AbbVie Inc - Company Profile
Powered by 
All the sales intelligence you need on AbbVie Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how AbbVie Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with AbbVie Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
View moreAbbVie Inc (AbbVie) is a specialty biopharmaceutical company engaged in the discovery, development, manufacturing, and commercialization of drugs to treat complex and serious diseases. The company focuses on the therapy areas of rheumatology, dermatology, gastroenterology, oncology, neuroscience, eye care, aesthetics, infectious diseases, pulmonology, endocrinology, among others. It also offers contract manufacturing services to manufacture antibody drug conjugates, aseptic fill finish, mAbs and mAb, custom API’s and eye care solutions, among others. AbbVie offers its products to patients globally through physicians, wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers, among others. The company operates its manufacturing facilities in the US, Italy, Ireland, Costa Rica, Germany, France, and Singapore. AbbVie is headquartered in North Chicago, Illinois, the US.
Headquarters
United States of America
Address
1 North Waukegan Road, North Chicago, Illinois, 60064
Website
www.abbvie.com
Telephone
1 847 9327900
No of Employees
57,000
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ABBV (NYSE)
Revenue (2024)
$61.2B
8.6%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-1.2%
(2024 vs 2023)
Market Cap*
$461.3B
Net Profit Margin (2024)
XYZ
-9.0%
(2024 vs 2023)
* As of and is in US$
AbbVie Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | Juvederm |
| Immunology Products for Treating: | Humira |
| Rheumatoid Arthritis | Rinvoq |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Asset Purchase | In July, the company acquired a device manufacturing facility in Tempe, Arizona, and associated intellectual property from West Pharmaceutical Services. |
| 2026 | Contracts/Agreements | In June, the company signed an agreement to acquire Apogee Therapeutics. |
| 2026 | Regulatory Approval | In June, the company secured approval from the European Commission for AQUIPTA (atogepant) for the acute treatment of migraine in adults with or without aura. |
Competitor Comparison
| Key Parameters | AbbVie Inc | Johnson & Johnson | Eli Lilly and Co | Merck & Co Inc | Pfizer Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | North Chicago | New Brunswick | Indianapolis | Rahway | New York City |
| State/Province | Illinois | New Jersey | Indiana | New Jersey | New York |
| No. of Employees | 57,000 | 138,200 | 50,605 | 75,000 | 75,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Robert A. Michael | Chief Executive Officer; Chairman | Executive Board | 2025 | 55 |
| Scott T. Reents | Executive Vice President; Chief Financial Officer | Senior Management | 2022 | 58 |
| Linda Ray | Chief Information Officer; Senior Vice President | Senior Management | - | - |
| Roopal Thakkar, M.D. | Chief Scientific Officer; Executive Vice President - Research & Development | Senior Management | 2024 | 54 |
| Jeffrey R. Stewart | Chief Commercial Officer; Executive Vice President | Senior Management | 2020 | 57 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer